Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery and delivery technologies, announced that Chief Business Officer George Tziras will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for Nov. 10–12, 2025, in Boston, Massachusetts. This participation underscores Cybin's commitment to advancing novel treatments for mental health conditions with significant unmet need.
The company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer effective and durable results for patients. Additionally, Cybin is advancing CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder. These programs are part of a broader research pipeline focused on 5-HT-receptor targeted compounds.
Cybin's presence at the Guggenheim conference is significant as it provides a platform to discuss the company's progress and the implications of its research. The conference brings together healthcare innovators, investors, and industry leaders, offering Cybin an opportunity to showcase its late-stage breakthrough neuropsychiatry pipeline. With promising class-leading data, Cybin aims to change the mental health treatment landscape by introducing novel drugs that address the large unmet need for people suffering from mental health conditions.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland. The company's participation in the conference reflects its ongoing efforts to engage with the investment community and highlight the potential of its proprietary technologies. For more details, the full press release is available at https://ibn.fm/uqBYE. Investors can also access the latest news and updates relating to CYBN in the company’s newsroom at https://ibn.fm/CYBN.
The announcement is important as it signals Cybin's continued momentum in clinical development and its strategic efforts to secure funding and partnerships through investor conferences. As mental health remains a critical global issue, Cybin's advancements in psychedelic-based therapeutics could represent a paradigm shift in treatment options. The fireside chat at the Guggenheim conference will likely cover Cybin's clinical data, regulatory milestones, and future plans, providing valuable insights for stakeholders.
